Wyeth, the US drugmaker, on Thursday signalled a more aggressive stance on acquisitions on the back of a strong second quarter.

Bob Essner, chief executive, said the company’s strengthening balance sheet allowed it to review how it would use cash, which included steadily increasing the dividend over the last few years. Using it for acquisitions, however, could help the group the most.